Immune checkpoint inhibitors (ICPI) have revolutionized cancer therapy and provided
clinical benefit to thousands of patients. Despite durable responses in many tumor types, the …

BACKGROUND Immunotherapy, especially the use of immune checkpoint inhibitors, has
revolutionized the management of several different cancer types in recent years. However …

PURPOSE Immune checkpoint inhibition (ICI) therapy represents one of the great advances
in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still
constrained by lack of response and toxicity. Biomarkers of response may facilitate drug …

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …

Immune checkpoint inhibitors have shown great potential in treating solid tumors, inducing
durable remission and prolonged survival time in responders. Despite their promise, a large …

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for
patients with many advanced malignancies, only 15–60% of patients respond, leaving a …

Background Immune checkpoint inhibitors (ICPI) are a tumor agnostic treatment. However,
trials of their use have been site specific. Here we summarize the trial data and explore the …

Despite the success of immune checkpoint blockade as a strategy for activating an antitumor
immune response and promoting cancer regression, only a subset of patients have durable …